Epigenetic remodeling of chromatin architecture: Exploring tumor differentiation therapies in mesenchymal stem cells and sarcomas

Current Stem Cell Research and Therapy

Volumn 5, Issue 1, 2010, Pages 63-73

  Siddiqi, Sara ^a   Mills, Joslyn ^b   Matushansky, Igor ^b  

^a Graduate School of Arts and Science   (United States)

^b Columbia University ^*  (United States)

Author keywords

Chromatin; Differentiation; Histone deacetylase inhibitor; Mesenchymal stem cell; Sarcoma

Indexed keywords

ALIPHATIC CARBOXYLIC ACID; BENZAMIDE DERIVATIVE; BUTYRIC ACID; CYCLOPEPTIDE; DIMETHYL SULFOXIDE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HISTONE METHYLTRANSFERASE; HYDROXAMIC ACID DERIVATIVE; RETINOIC ACID; TRICHOSTATIN A; VORINOSTAT;

CANCER GENETICS; CANCER GRADING; CARCINOGENESIS; CELL DIFFERENTIATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN STRUCTURE; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DEHYDRATION; EPIGENETICS; FATIGUE; GENE EXPRESSION; GENETIC TRANSCRIPTION; GLIOBLASTOMA; HUMAN; LYMPHOMA; MELANOMA; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SARCOMA; TUMOR DIFFERENTIATION;

ANIMALS; CELL DIFFERENTIATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; MESENCHYMAL STEM CELLS; SARCOMA; TRETINOIN;

EID: 77949409909     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488810790442859     Document Type: Review

References (153)

1. Tang N, Song WX, Luo J, Haydon RC, He TC. Osteosarcoma development and stem cell differentiation. Clin Orthop Relat Res 2008; 466(9): 2114-30.
2. Rasmussen TP. Developmentally-poised chromatin of embryonic stem cells. Front Biosci 2008; 13: 1568-77.
3. Shukla V, Vaissiere T, Herceg Z. Histone acetylation and chromatin signature in stem cell identity and cancer. Mutat Res 2008; 637(1-2): 1-15.
4. Freitas MA, Sklenar AR, Parthun MR. Application of mass spectrometry to the identification and quantification of histone post-translational modifications. J Cell Biochem 2004; 92(4): 691-700.
5. Carrozza MJ, Utley RT, Workman JL, Côté J. The diverse functions of histone acetyltransferase complexes. Trends Genet 2003; 19(6): 321-9.
6. Condorelli F, Gnemmi I, Vallario A, Genazzani AA, Canonico PL. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. Br J Pharmacol 2008; 153(4): 657-68.
7. Rice JC, Allis CD. Histone methylation versus histone acetylation: new insights into epigenetic regulation. Curr Opin Cell Biol 2001; 13(3): 263-73.
8. Baxter CS, Byvoet P. CMR studies of protein modification. Progressive decrease in charge density at the epsilon-amino function of lysine with increasing methyl substitution. Biochem Biophys Res Commun 1975; 64(2): 514-8.
9. Strahl BD, Ohba R, Cook RG, Allis CD. Methylation of histone H3 at lysine 4 is highly conserved and correlates with transcriptionally active nuclei in Tetrahymena. Proc Natl Acad Sci USA 1999; 96(26): 14967-72.
10. Heard E, Rougeulle C, Arnaud D, Avner P, Allis CD, Spector DL. Methylation of histone H3 at Lys-9 is an early mark on the X chromosome during X inactivation. Cell 2001; 107(6): 727-38.
11. Peters AH, Kubicek S, Mechtler K, et al. Partitioning and plasticity of repressive histone methylation states in mammalian chromatin. Mol Cell 2003; 12(6): 1577-89.
12. Vakoc CR, Mandat SA, Olenchock BA, Blobel GA. Histone H3 lysine 9 methylation and HP1gamma are associated with transcription elongation through mammalian chromatin. Mol Cell 2005; 19(3): 381-91.
13. Wiencke JK, Zheng S, Morrison Z, Yeh RF. Differentially expressed genes are marked by histone 3 lysine 9 trimethylation in human cancer cells. Oncogene 2008; 27(17): 2412-21.
14. D'Alessio AC, Szyf M. Epigenetic tete-a-tete: the bilateral relationship between chromatin modifications and DNA methylation. Biochem Cell Biol 2006; 84(4): 463-76.
15. Turek-Plewa J, Jagodzinski PP. The role of mammalian DNA methyltransferases in the regulation of gene expression. Cell Mol Biol Lett 2005; 10(4): 631-47.
16. Kim JK, Samaranayake M, Pradhan S. Epigenetic mechanisms in mammals. Cell Mol Life Sci 2009; 66(4): 596-612.
17. Razin A, Szyf M. DNA methylation patterns. Formation and function. Biochim Biophys Acta 1984; 782(4): 331-42.
18. Chen T, Ueda Y, Dodge JE, Wang Z, Li E. Establishment and maintenance of genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and Dnmt3b. Mol Cell Biol 2003; 23(16): 5594-605.
19. Kim GD, Ni J, Kelesoglu N, Roberts R J, Pradhan S. Co-operation and communication between the human maintenance and de novo DNA (cytosine-5) methyltransferases. EMBO J 2002; 21(15): 4183-95.
20. Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293(5532): 1074-80.
21. Huang RC, Bonnerv J. Histone, a suppressor of chromosomal RNA synthesis. Proc Natl Acad Sci USA 1962; 48: 1216-22.
22. Moore BC. Histones and Differentiation. Proc Natl Acad Sci USA 1963; 50: 1018-26.
23. Smart JE, Bonner J. Selective dissociation of histones from chromatin by sodium deoxycholate. J Mol Biol 1971; 58(3): 651-9.
24. Panyim S, Jensen RH, Chalkley R. Proteolytic contamination of calf thymus nucleohistone and its inhibition. Biochim Biophys Acta 1968; 160(2): 252-5.
25. Monahan JJ, Hall RH. Chromatin, and gene regulation in eukaryotic cells at the transcriptional level. CRC Crit Rev Biochem 1974; 2(1): 67-112.
26. Davie JR. Inhibition of histone deacetylase activity by butyrate. J Nutr 2003; 133(7 Suppl): 2485S-93S.
27. Kruh J. Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol Cell Biochem 1982; 42(2): 65-82.
28. Thompson EM. Chromatin structure and gene expression in the preimplantation mammalian embryo. Reprod Nutr Dev 1996; 36(6): 619-35.
29. Patterton D, Wolffe AP. Developmental roles for chromatin and chromosomal structure. Dev Biol 1996; 173(1): 2-13.
30. van Daal A, Elgin SC. A histone variant, H2AvD, is essential in Drosophila melanogaster. Mol Biol Cell 1992; 3(6): 593-602.
31. Stein GS, Lian JB, Stein JL, Van Wijnen AJ, Montecino M. Transcriptional control of osteoblast growth and differentiation. Physiol Rev 1996; 76(2): 593-629.
32. Tachibana M, Sugimoto K, Nozaki M, et al. G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Genes Dev 2002; 16(14): 1779-91.
33. Surani MA, Hayashi K, Hajkova P. Genetic and epigenetic regulators of pluripotency. Cell 2007; 128(4): 747-62.
34. Li E, Bestor TH, Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 1992; 69(6): 915-26.
35. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 2009; 10(1): 32-42.
36. Wen B, Wu H, Shinkai Y, Irizarry RA, Feinberg AP. Large histone H3 lysine 9 dimethylated chromatin blocks distinguish differentiated from embryonic stem cells. Nat Genet 2009; 41(2): 246-50.
37. Meshorer E, Yellajoshula D, George E, Scambler PJ, Brown DT, Misteli T. Hyperdynamic plasticity of chromatin proteins in pluripotent embryonic stem cells. Dev Cell 2006; 10(1): 105-16.
38. Miranda TB, Jones PA. DNA methylation: the nuts and bolts of repression. J Cell Physiol 2007; 213(2): 384-90.
39. Guidi CJ, Sands AT, Zambrowicz BP, et al. Disruption of Ini1 leads to peri-implantation lethality and tumorigenesis in mice. Mol Cell Biol 2001; 21(10): 3598-603.
40. Hamatani T, Ko MSh, Yamada M, et al. Global gene expression profiling of preimplantation embryos. Hum Cell 2006; 19(3): 98-117.
41. Wu H, Sun YE. Epigenetic regulation of stem cell differentiation. Pediatr Res 2006; 59(4 Pt 2): 21R-5R.
42. Mikkelsen TS, Ku M, Jaffe DB, et al. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. Nature 2007; 448(7153): 553-60.
43. Giambra V, Volpi S, Emelyanov AV, et al. Pax5 and linker histone H1 coordinate DNA methylation and histone modifications in the 3′ regulatory region of the immunoglobulin heavy chain locus. Mol Cell Biol 2008; 28(19): 6123-33.
44. Bloushtain-Qimron N, Yao J, Shipitsin M, Maruyama R, Polyak K. Epigenetic patterns of embryonic and adult stem cells. Cell Cycle 2009; 8(6): 809-17.
45. van der Maarel SM. Epigenetic mechanisms in health and disease. Ann Rheum Dis 2008; 67 (Suppl 3): 97-100.
46. Available from: http://clinicaltrials.gov/. 2009.
47. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983; 301(5895): 89-92.
48. Schuettengruber B, Chourrout D, Vervoort M, Leblanc B, Cavalli G. Genome regulation by polycomb and trithorax proteins. Cell 2007; 128(4): 735-45.
49. Lewis EB. A gene complex controlling segmentation in Drosophila. Nature 1978; 276(5688): 565-70.
50. Levine SS, Weiss A, Erdjument-Bromage H, Shao Z, Tempst P, Kingston RE. The core of the polycomb repressive complex is compositionally and functionally conserved in flies and humans. Mol Cell Biol 2002; 22(17): 6070-8.
51. Kirmizis A, Bartley SM, Kuzmichev A, et al. Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev 2004; 18(13): 1592-605.
52. Dellino GI, Schwartz YB, Farkas G, McCabe D, Elgin SC, Pirrotta V. Polycomb silencing blocks transcription initiation. Mol Cell 2004; 13(6): 887-93.
53. Shao Z, Raible F, Mollaaghababa R, et al. Stabilization of chromatin structure by PRC1, a Polycomb complex. Cell 1999; 98(1): 37-46.
54. Kuzmichev A, Margueron R, Vaquero A, et al. Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc Natl Acad Sci USA 2005; 102(6): 1859-64.
55. Visser HP, Gunster MJ, Kluin-Nelemans H, et al. The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol 2001; 112(4): 950-8.
56. van Leenders GJ, Dukers D, Hessels D, et al. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol 2007; 52(2): 455-63.
57. Bea S, Tort F, Pinyol M, et al. BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 2001; 61(6): 2409-12.
58. Vonlanthen S, Heighway J, Altermatt HJ, et al. The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer 2001; 84(10): 1372-6.
59. Kim JH, Yoon SY, Kim CN, et al. The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett 2004; 203(2): 217-24.
60. Gil J, Bernard D, Peters G. Role of polycomb group proteins in stem cell self-renewal and cancer. DNA Cell Biol 2005; 24(2): 117-25.
61. Boyer LA, Plath K, Zeitlinger J, et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 2006; 441(7091): 349-53.
62. Schlesinger Y, Straussman R, Keshet I, et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007; 39(2): 232-6.
63. Noer A, Lindeman LC, Collas P. Histone h3 modifications associated with differentiation and long-term culture of mesenchymal adipose stem cells. Stem Cells Dev 2009; 18(5): 725-36.
64. Sadikovic B, Andrews J, Rodenhiser DI. DNA methylation analysis using CpG microarrays is impaired in benzopyrene exposed cells. Toxicol Appl Pharmacol 2007; 225(3): 300-9.
65. Matushansky I, Hernando E, Socci ND, et al. Derivation of sarcomas from mesenchymal stem cells via inactivation of the Wnt pathway. J Clin Invest 2007; 117(11): 3248-57.
66. Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest 2006; 116(5): 1202-9.
67. Ross SE, Hemati N, Longo KA, et al. Inhibition of adipogenesis by Wnt signaling. Science 2000; 289(5481): 950-3.
68. Bernstein BE, Mikkelsen TS, Xie X, et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006; 125(2): 315-26.
69. Krampera M, Pizzolo G, Aprili G, Franchini M. Mesenchymal stem cells for bone, cartilage, tendon and skeletal muscle repair. Bone 2006; 39(4): 678-83.
70. Zuk PA, Zhu M, Ashjian P, et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002; 13(12): 4279-95.
71. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284(5411): 143-7.
72. Smith JR, Pochampally R, Perry A, Hsu SC, Prockop DJ. Isolation of a highly clonogenic and multipotential subfraction of adult stem cells from bone marrow stroma. Stem Cells 2004; 22(5): 823-31.
73. Crisan M, Yap S, Casteilla L, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008; 3(3): 301-13.
74. Delorme B, Yap S, Casteilla L, et al. Specific lineage-priming of bone marrow mesenchymal stem cells provides the molecular framework for their plasticity. Stem Cells 2009; 27(5): 1142-51.
75. Barker N. The canonical Wnt/beta-catenin signalling pathway. Methods Mol Biol 2008; 468: 5-15.
76. Takigawa Y, Brown AM. Wnt signaling in liver cancer. Curr Drug Targets 2008; 9(11): 1013-24.
77. Robinson DR, CR Zylstra, BO Williams. Wnt signaling and prostate cancer. Curr Drug Targets 2008; 9(7): 571-80.
78. Matushansky I, Maki RG, Cordon-Cardo C. A context dependent role for Wnt signaling in tumorigenesis and stem cells. Cell Cycle 2008; 7(6): 720-4.
79. Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O. Mesenchymal stem cell features of Ewing tumors. Cancer Cell 2007; 11(5): 421-9.
80. Torchia EC, Jaishankar S, Baker SJ. Ewing tumor fusion proteins block the differentiation of pluripotent marrow stromal cells. Cancer Res 2003; 63(13): 3464-8.
81. Matushansky I, Hernando E, Socci ND, et al. A developmental model of sarcomagenesis defines a differentiation-based classification for liposarcomas. Am J Pathol 2008; 172(4): 1069-80.
82. DeVita VT. Cancer: Principles & Practice of Oncology. 8 ed. Lippincott Williams & Wilkins 2008.
83. Haydon RC, HH Luu, TC He. Osteosarcoma and osteoblastic differentiation: a new perspective on oncogenesis. Clin Orthop Relat Res 2007; 454: 237-46.
84. Kansara M, Thomas DM. Molecular pathogenesis of osteosarcoma. DNA Cell Biol 2007; 26(1): 1-18.
85. Jain M, Arvanitis C, Chu K, et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 2002; 297(5578): 102-4.
86. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006; 7(1): 21-33.
87. Dick JE. Stem cell concepts renew cancer research. Blood 2008; 112(13): 4793-807.
88. Orfao A, Schmitz G, Brando B, et al. Clinically useful information provided by the flow cytometric immunophenotyping of hematological malignancies: current status and future directions. Clin Chem 1999; 45(10): 1708-17.
89. Krivtsov AV, Twomey D, Feng Z, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLLAF9. Nature 2006; 442(7104): 818-22.
90. Pierce GB, Speers WC. Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. Cancer Res 1988; 48(8): 1996-2004.
91. Maden M. The role of retinoic acid in embryonic and post-embryonic development. Proc Nutr Soc 2000; 59(1): 65-73.
92. Malashicheva AB, Kisliakova TV, Pospelov VA. G1 block of the cell cycle during differentiation of F9 cells correlates with accumulation of inhibitors of the activity of cyclin-kinase complexes of proteins p21/Waf1 and p27/Kip. Tsitologiia 2002; 44(7): 649-55.
93. Sun Y, Zuo L, Xu C, Shen T, Pan H, Zhang Z. Apoptosis and differentiation induced by sodium selenite combined with all-trans retinoic acid (ATRA) in NB4 cells. Zhonghua Xue Ye Xue Za Zhi 2002; 23(12): 628-30.
94. Lopatina NG, Poole JC, Saldanha SN, et al. Control mechanisms in the regulation of telomerase reverse transcriptase expression in differentiating human teratocarcinoma cells. Biochem Biophys Res Commun 2003; 306(3): 650-9.
95. Strickland S, Mahdavi V. The induction of differentiation in teratocarcinoma stem cells by retinoic acid. Cell 1978; 15(2): 393-403.
96. Trump DL. Retinoids in bladder, testis and prostate cancer: epidemiologic, pre-clinical and clinical observations. Leukemia 1994; 8 (Suppl 3): S50-4.
97. Segalla S, Rinaldi L, Kilstrup-Nielsen C, et al. Retinoic acid receptor alpha fusion to PML affects its transcriptional and chromatin-remodeling properties. Mol Cell Biol 2003; 23(23): 8795-808.
98. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6(1): 38-51.
99. Warrell RP Jr, Frankel SR, Miller WH Jr, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991; 324(20): 1385-93.
100. Marill J, Capron CC, Idres N, Chabot GG. Human cytochrome P450s involved in the metabolism of 9-cis- and 13-cis-retinoic acids. Biochem Pharmacol 2002; 63(5): 933-43.
101. Larson RS, MS Tallman. Retinoic acid syndrome: manifestations, pathogenesis, and treatment. Best Pract Res Clin Haematol 2003; 16(3): 453-61.
102. Ebert PS, Malinin GI. Induction of erythroid differentiation in Friend murine erythroleukemic cells by inorganic selenium compounds. Biochem Biophys Res Commun 1979; 86(2): 340-9.
103. Dokmanovic M, Perez G, Xu W, et al. Histone deacetylase inhibitors selectively suppress expression of HDAC7. Mol Cancer Ther 2007; 6(9): 2525-34.
104. Richon VM, Webb Y, Merger R, et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci USA 1996; 93(12): 5705-8.
105. Griffiths EA, Gore SD. DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes. Semin Hematol 2008; 45(1): 23-30.
106. Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21(1): 103-7.
107. Zhu L, Skoultchi AI. Coordinating cell proliferation and differentiation. Curr Opin Genet Dev 2001; 11(1): 91-7.
108. Uchida H, Maruyama T, Nagashima T, Asada H, Yoshimura Y. Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin. Endocrinology 2005; 146(12): 5365-73.
109. Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 2001; 61(23): 8492-7.
110. Svechnikova I, Almqvist PM, Ekstrom TJ. HDAC inhibitors effectively induce cell type-specific differentiation in human glioblastoma cell lines of different origin. Int J Oncol 2008; 32(4): 821-7.
111. Yu IT, Park JY, Kim SH, Lee JS, Kim YS, Son H. Valproic acid promotes neuronal differentiation by induction of proneural factors in association with H4 acetylation. Neuropharmacology 2009; 56(2): 473-80.
112. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005; 23(17): 3923-31.
113. Rosato RR, Grant S. Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin Ther Targets 2005; 9(4): 809-24.
114. Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007; 5(10): 981-9.
115. Rephaeli A, Blank-Porat D, Tarasenko N, et al. In vivo and in vitro antitumor activity of butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, in human prostate cancer. Int J Cancer 2005; 116(2): 226-35.
116. Ito T, Ouchida M, Morimoto Y, et al. Significant growth suppression of synovial sarcomas by the histone deacetylase inhibitor FK228 in vitro and in vivo. Cancer Lett 2005; 224(2): 311-9.
117. Lubieniecka JM, de Bruijn DR, Su L, et al. Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma. Cancer Res 2008; 68(11): 4303-10.
118. Nguyen A, Su L, Campbell B, et al. Synergism of heat shock protein 90 and histone deacetylase inhibitors in synovial sarcoma. Sarcoma 2009; 2009: 794901.
119. De Schutter H, Kimpe M, Isebaert S, Nuyts S. A systematic assessment of radiation dose enhancement by 5-Aza-2′-deoxycytidine and histone deacetylase inhibitors in head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2009; 73(3): 904-12.
120. Garcia-Manero G, Yang H, Bueso-Ramos C, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008; 111(3): 1060-6.
121. Walton TJ, Li G, Seth R, McArdle SE, Bishop MC, Rees RC. DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines. Prostate 2008; 68(2): 210-22.
122. Kato H, Ohta S, Koshida S, et al. Expression of pericyte, mesangium and muscle markers in malignant rhabdoid tumor cell lines: differentiation-induction using 5-azacytidine. Cancer Sci 2003; 94(12): 1059-65.
123. Constantinides PG, Jones PA, Gevers W. Functional striated muscle cells from non-myoblast precursors following 5-azacytidine treatment. Nature 1977. 267(5609): 364-6.
124. Makino S, Fukuda K, Miyoshi S, et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 1999; 103(5): 697-705.
125. Zhou GS, Zhang XL, Wu JP, et al. 5-Azacytidine facilitates osteogenic gene expression and differentiation of mesenchymal stem cells by alteration in DNA methylation. Cytotechnology 2009.
126. Wakitani S, Saito T, Caplan AI. Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine. Muscle Nerve 1995; 18(12): 1417-26.
127. Cole PA. Chemical probes for histone-modifying enzymes. Nat Chem Biol 2008; 4(10): 590-7.
128. Vaissiere T, Sawan C, Herceg Z. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. Mutat Res 2008; 659(1-2): 40-8.
129. Vogelauer M, Wu J, Suka N, Grunstein M. Global histone acetylation and deacetylation in yeast. Nature 2000; 408(6811): 495-8.
130. Kass SU, Landsberger N, Wolffe AP. DNA methylation directs a time-dependent repression of transcription initiation. Curr Biol 1997; 7(3): 157-65.
131. Rountree MR, Selker EU. DNA methylation inhibits elongation but not initiation of transcription in Neurospora crassa. Genes Dev 1997; 11(18): 2383-95.
132. Jones PL, Veenstra GJ, Wade PA, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998; 19(2): 187-91.
133. Bird AP, Wolffe AP. Methylation-induced repression - belts, braces, and chromatin. Cell 1999; 99(5): 451-4.
134. Kimura H, Shiota K. Methyl-CpG-binding protein, MeCP2, is a target molecule for maintenance DNA methyltransferase, Dnmt1. J Biol Chem 2003; 278(7): 4806-12.
135. Mutskov V, Felsenfeld G. Silencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9. EMBO J 2004; 23(1): 138-49.
136. Ben-Porath I, Cedar H. Epigenetic crosstalk. Mol Cell 2001; 8(5): 933-5.
137. Richards EJ, Elgin SC. Epigenetic codes for heterochromatin formation and silencing: rounding up the usual suspects. Cell 2002; 108(4): 489-500.
138. Fiskus W, Pranpat M, Balasis M, et al. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Mol Cancer Ther 2006; 5(12): 3096-104.
139. Ou JN, Torrisani J, Unterberger A, et al. Histone deacetylase inhibitor Trichostatin A induces global and gene-specific DNA demethylation in human cancer cell lines. Biochem Pharmacol 2007; 73(9):1297-307.
140. Kawamoto K, Okino ST, Place RF, et al. Epigenetic modifications of RASSF1A gene through chromatin remodeling in prostate cancer. Clin Cancer Res 2007; 13(9): 2541-8.
141. Vaquero A, Scher M, Erdjument-Bromage H, Tempst P, Serrano L, Reinberg D. SIRT1 regulates the histone methyl-transferase SUV39H1 during heterochromatin formation. Nature 2007; 450(7168): 440-4.
142. Vaute O, Nicolas E, Vandel L, Trouche D. Functional and physical interaction between the histone methyl transferase Suv39H1 and histone deacetylases. Nucleic Acids Res 2002; 30(2): 475-81.
143. Kim SM, Kee HJ, Choe N, et al. The histone methyltransferase activity of WHISTLE is important for the induction of apoptosis and HDAC1-mediated transcriptional repression. Exp Cell Res 2007; 313(5): 975-83.
144. Fuks F, Hurd PJ, Deplus R, Kouzarides T. The DNA methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase. Nucleic Acids Res 2003; 31(9): 2305-12.
145. Tamaru H, Selker EU. A histone H3 methyltransferase controls DNA methylation in Neurospora crassa. Nature 2001; 414(6861): 277-83.
146. Bannister AJ, Zegerman P, Partridge JF, et al. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature 2001; 410(6824): 120-4.
147. Lachner M, O'Carroll D, Rea S, Mechtler K, Jenuwein T. Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature 2001; 410(6824): 116-20.
148. Yan Q, Huang J, Fan T, Zhu H, Muegge K. Lsh, a modulator of CpG methylation, is crucial for normal histone methylation. EMBO1 J 2003; 22(19): 5154-62.
149. Zhu H, Geiman TM, Xi S, et al. Lsh is involved in de novo methylation of DNA. EMBO J 2006; 25(2): 335-45.
150. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002; 16(1): 6-21.
151. Fuks F, Hurd PJ, Wolf D, Nan X, Bird AP, Kouzarides T. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem 2003; 278(6): 4035-40.
152. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999; 99(3): 247-57.
153. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414(6859): 105-11.